Temat: "CLOPIDOGREL" - OpacWWW

Skocz do pozycji: 1.

Tytuł:: Clopidogrel-induced non-diabetic hypoglycemia reported from Tikur Anbessa Specialized Hospital, Addis Ababa, Ethiopia: a case report.
Autorzy:: Belay KE; Department of Internal Medicine, Endocrinology and Metabolism Unit, Addis Ababa University, Addis Ababa, Ethiopia.
Urge SB; Department of Internal Medicine, Endocrinology and Metabolism Unit, Addis Ababa University, Addis Ababa, Ethiopia.
Birhan YA; Department of Internal Medicine, Cardiology Unit, Addis Ababa University, Addis Ababa, Ethiopia.
Efrem P; Department of Internal Medicine, Endocrinology and Metabolism Unit, Addis Ababa University, Addis Ababa, Ethiopia.
Alemneh TA; Department of Internal Medicine, Endocrinology and Metabolism Unit, Addis Ababa University, Addis Ababa, Ethiopia. .; Pokaż więcej
Źródło:: Journal of medical case reports [J Med Case Rep] 2023 Nov 05; Vol. 17 (1), pp. 460. Date of Electronic Publication: 2023 Nov 05.
Typ publikacji:: Case Reports; Journal Article
MeSH Terms:: Acute Coronary Syndrome*
Hypoglycemia*/chemically induced
Humans ; Male ; Adult ; Clopidogrel/adverse effects ; Blood Glucose ; Ethiopia ; Hospitals

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 2.

Tytuł:: Comparison of Ticagrelor and Clopidogrel in Elective Coronary Stenting: A Double Blind Randomized Clinical Trial.
Autorzy:: Mehdizadeh Parizi M; Professor Kojuri Cardiology Clinic, Shiraz, Iran.
Golchin Vafa R; Professor Kojuri Cardiology Clinic, Shiraz, Iran.
Ahmadi A; Professor Kojuri Cardiology Clinic, Shiraz, Iran.
Heydarzade R; Professor Kojuri Cardiology Clinic, Shiraz, Iran.
Sadeghi M; Professor Kojuri Cardiology Clinic, Shiraz, Iran.
Khademolhossseini A; Professor Kojuri Cardiology Clinic, Shiraz, Iran.
Amiri F; Professor Kojuri Cardiology Clinic, Shiraz, Iran.
Khoshnood Mansorkhani S; Professor Kojuri Cardiology Clinic, Shiraz, Iran.
Tavan A; Professor Kojuri Cardiology Clinic, Shiraz, Iran.
Hosseini N; Professor Kojuri Cardiology Clinic, Shiraz, Iran.
Montaseri M; Professor Kojuri Cardiology Clinic, Shiraz, Iran.
Hosseini SA; Professor Kojuri Cardiology Clinic, Shiraz, Iran.
Kojuri J; Professor Kojuri Cardiology Clinic, Shiraz, Iran.; Cardiology Department, Shiraz University of Medical Sciences, Shiraz, Iran.; Clinical Education Research Center, Shiraz University of Medical Sciences, Shiraz, Iran.; Pokaż więcej
Źródło:: Journal of interventional cardiology [J Interv Cardiol] 2023 Dec 26; Vol. 2023, pp. 5544440. Date of Electronic Publication: 2023 Dec 26 (Print Publication: 2023).
Typ publikacji:: Randomized Controlled Trial; Journal Article
MeSH Terms:: Percutaneous Coronary Intervention*/adverse effects
Acute Coronary Syndrome*/therapy
Humans ; Clopidogrel/adverse effects ; Ticagrelor/therapeutic use ; Ticagrelor/adverse effects ; Platelet Aggregation Inhibitors/adverse effects ; Purinergic P2Y Receptor Antagonists/adverse effects ; Hemorrhage/epidemiology ; Aspirin/therapeutic use ; Dyspnea/etiology ; Stents ; Treatment Outcome

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 3.

Tytuł:: Prescription patterns of P2Y12 inhibitors following revascularization in the United States: 2013-2018.
Autorzy:: Kumar A; Department of Pharmacy Practice and Administrative Sciences, James L. Winkle College of Pharmacy, University of Cincinnati, Cincinnati, Ohio, USA.
Lutsey PL; Division of Epidemiology and Community Health, University of Minnesota, School of Public Health, Minneapolis, Minnesota, USA.
St Peter WL; Department of Pharmaceutical Care and Health Systems, University of Minnesota, College of Pharmacy, Minneapolis, Minnesota, USA.
Schommer JC; Department of Pharmaceutical Care and Health Systems, University of Minnesota, College of Pharmacy, Minneapolis, Minnesota, USA.
Van't Hof JR; Cardiovascular Division, Lillehei Heart Institute, University of Minnesota Medical School, Minneapolis, Minnesota, USA.
Rajpurohit A; Department of Pharmaceutical Care and Health Systems, University of Minnesota, College of Pharmacy, Minneapolis, Minnesota, USA.
Farley JF; Department of Pharmaceutical Care and Health Systems, University of Minnesota, College of Pharmacy, Minneapolis, Minnesota, USA.; Pokaż więcej
Źródło:: Clinical and translational science [Clin Transl Sci] 2023 Oct; Vol. 16 (10), pp. 1886-1897. Date of Electronic Publication: 2023 Aug 03.
Typ publikacji:: Journal Article; Research Support, N.I.H., Extramural
MeSH Terms:: Coronary Artery Disease*/drug therapy
Acute Coronary Syndrome*/chemically induced
Acute Coronary Syndrome*/drug therapy
Humans ; United States/epidemiology ; Aged ; Clopidogrel/adverse effects ; Ticagrelor/adverse effects ; Platelet Aggregation Inhibitors/adverse effects ; Purinergic P2Y Receptor Antagonists/adverse effects ; Prescriptions ; Treatment Outcome

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 4.

Tytuł:: The effect of ticagrelor on coronary microvascular function after PCI in patients with ACS compared to clopidogrel: A systematic review and meta-analysis.
Autorzy:: Qiu X; Department of Cardiology, National Key Laboratory for Innovation and Transformation of Luobing Theory, The Key Laboratory of Cardiovascular Remodeling and Function Research, Chinese Ministry of Education, Chinese National Health Commission and Chinese Academy of Medical Sciences, Qilu Hospital of Shandong University, Jinan, China.
Li X; Department of Cardiology, National Key Laboratory for Innovation and Transformation of Luobing Theory, The Key Laboratory of Cardiovascular Remodeling and Function Research, Chinese Ministry of Education, Chinese National Health Commission and Chinese Academy of Medical Sciences, Qilu Hospital of Shandong University, Jinan, China.
Fu K; Department of Cardiology, National Key Laboratory for Innovation and Transformation of Luobing Theory, The Key Laboratory of Cardiovascular Remodeling and Function Research, Chinese Ministry of Education, Chinese National Health Commission and Chinese Academy of Medical Sciences, Qilu Hospital of Shandong University, Jinan, China.
Chen W; Department of Cardiology, National Key Laboratory for Innovation and Transformation of Luobing Theory, The Key Laboratory of Cardiovascular Remodeling and Function Research, Chinese Ministry of Education, Chinese National Health Commission and Chinese Academy of Medical Sciences, Qilu Hospital of Shandong University, Jinan, China.
Chen W; Department of Cardiology, National Key Laboratory for Innovation and Transformation of Luobing Theory, The Key Laboratory of Cardiovascular Remodeling and Function Research, Chinese Ministry of Education, Chinese National Health Commission and Chinese Academy of Medical Sciences, Qilu Hospital of Shandong University, Jinan, China.; Pokaż więcej
Źródło:: PloS one [PLoS One] 2023 Aug 29; Vol. 18 (8), pp. e0289243. Date of Electronic Publication: 2023 Aug 29 (Print Publication: 2023).
Typ publikacji:: Meta-Analysis; Systematic Review; Journal Article
MeSH Terms:: Acute Coronary Syndrome*/drug therapy
Acute Coronary Syndrome*/surgery
Percutaneous Coronary Intervention*
Humans ; Clopidogrel/therapeutic use ; Ticagrelor/therapeutic use ; Microcirculation

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 5.

Tytuł:: Lower Plasma miR-223 Level Is Associated with Clopidogrel Resistance in Acute Coronary Syndrome: A Systematic Review and Meta-Analysis.
Autorzy:: Cheng H; Department of Neurology, The First Affiliated Hospital of Chengdu Medical College, Chengdu, China.
Yang M; Department of Neurology, The First Affiliated Hospital of Chengdu Medical College, Chengdu, China.
Hao J; School of Bioscience and Technology, Cengdu Medical College, Chengdu, China.
Chen K; School of Public Health, Cengdu Medical College, Chengdu, China.
Tan Q; Department of Neurology, The First Affiliated Hospital of Chengdu Medical College, Chengdu, China.
He S; Department of Neurology, The First Affiliated Hospital of Chengdu Medical College, Chengdu, China.
Mao F; Department of Neurology, The First Affiliated Hospital of Chengdu Medical College, Chengdu, China.
Yang M; Department of Neurology, The First Affiliated Hospital of Chengdu Medical College, Chengdu, China.
Lin Y; Department of Neurology, The First Affiliated Hospital of Chengdu Medical College, Chengdu, China.; International Clinical Research Center, Cengdu Medical College, Chengdu, China.
Yang J; Department of Neurology, Sichuan Provincial People's Hospital, University of Electronic Science and Technology of China, Chengdu, China.; Pokaż więcej
Źródło:: Journal of interventional cardiology [J Interv Cardiol] 2023 Aug 17; Vol. 2023, pp. 9322188. Date of Electronic Publication: 2023 Aug 17 (Print Publication: 2023).
Typ publikacji:: Meta-Analysis; Systematic Review; Journal Article; Review
MeSH Terms:: Acute Coronary Syndrome*/blood
Acute Coronary Syndrome*/drug therapy
MicroRNAs*/blood
MicroRNAs*/genetics
Drug Resistance*/genetics
Humans ; Asian People ; Clopidogrel/therapeutic use ; Databases, Factual ; Biomarkers/blood

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 6.

Tytuł:: Safety outcomes of ticagrelor among patients with STE-ACS post streptokinase therapy-a retrospective observational study.
Autorzy:: Ueapornpanith P; Faculty of Pharmacy, Chiang Mai University, Chiang Mai, Thailand.
Buranakiti B; Pharmacy Department, Nakornping Hospital, Chiang Mai, Thailand.
Chotayaporn T; Department of Internal Medicine, Nakornping Hospital, Chiang Mai, Thailand.
Phrommintikul A; Faculty of Medicine, Department of Internal Medicine, Division of Cardiology, Chiang Mai University, Chiang Mai, Thailand.
Yoodee V; Faculty of Pharmacy, Chiang Mai University, Chiang Mai, Thailand.; Pokaż więcej
Źródło:: PloS one [PLoS One] 2023 Aug 04; Vol. 18 (8), pp. e0289721. Date of Electronic Publication: 2023 Aug 04 (Print Publication: 2023).
Typ publikacji:: Observational Study; Journal Article
MeSH Terms:: Percutaneous Coronary Intervention*/adverse effects
Acute Coronary Syndrome*/therapy
Humans ; Ticagrelor ; Clopidogrel/adverse effects ; Platelet Aggregation Inhibitors/therapeutic use ; Streptokinase/adverse effects ; Treatment Outcome ; Purinergic P2Y Receptor Antagonists/adverse effects ; Prasugrel Hydrochloride

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 7.

Tytuł:: Endothelial biomarkers and platelet reactivity on ticagrelor versus clopidogrel in patients after acute coronary syndrome with and without concomitant type 2 diabetes: a preliminary observational study.
Autorzy:: Chyrchel B; Second Department of Cardiology, Institute of Cardiology, Faculty of Medicine, Jagiellonian University Medical College, 2 Jakubowskiego Street, 30-688, Cracow, Poland. .; Department of Cardiology and Cardiovascular Interventions, University Hospital, 2 Jakubowskiego Street, 30-688, Cracow, Poland. .
Kruszelnicka O; Department of Coronary Artery Disease and Heart Failure, Institute of Cardiology, Faculty of Medicine, Jagiellonian University Medical College, 80 Prądnicka Street, 31-202, Cracow, Poland.
Surdacki A; Second Department of Cardiology, Institute of Cardiology, Faculty of Medicine, Jagiellonian University Medical College, 2 Jakubowskiego Street, 30-688, Cracow, Poland.; Department of Cardiology and Cardiovascular Interventions, University Hospital, 2 Jakubowskiego Street, 30-688, Cracow, Poland.; Pokaż więcej
Źródło:: Cardiovascular diabetology [Cardiovasc Diabetol] 2022 Nov 17; Vol. 21 (1), pp. 249. Date of Electronic Publication: 2022 Nov 17.
Typ publikacji:: Observational Study; Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:: Acute Coronary Syndrome*/diagnosis
Acute Coronary Syndrome*/drug therapy
Clopidogrel*/therapeutic use
Diabetes Mellitus, Type 2*/diagnosis
Diabetes Mellitus, Type 2*/drug therapy
Ticagrelor*/therapeutic use
Aged ; Female ; Humans ; Male ; Middle Aged ; Biomarkers ; Platelet Aggregation Inhibitors/therapeutic use ; Stroke Volume ; Ventricular Function, Left

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 8.

Tytuł:: P2Y12 Inhibitors in Acute Coronary Syndromes: A Real-World, Community-Based Comparison of Ischemic and Bleeding Outcomes.
Autorzy:: Sachdeva A; Division of Cardiology, Kaiser Permanente Northern California, Walnut Creek, California, USA.
Mutyala R; Drexel University College of Medicine, Philadelphia, Pennsylvania, USA.
Mantri N; Division of Cardiology, Kaiser Permanente Northern California, San Francisco, California, USA.
Zhu S; Division of Research, Kaiser Permanente Northern California, Oakland, California, USA.
McNulty E; Division of Cardiology, Kaiser Permanente Northern California, San Francisco, California, USA.; Division of Research, Kaiser Permanente Northern California, Oakland, California, USA.
Solomon M; Division of Research, Kaiser Permanente Northern California, Oakland, California, USA.; Division of Cardiology, Kaiser Permanente Northern California, Oakland, California, USA.; Pokaż więcej
Źródło:: Journal of interventional cardiology [J Interv Cardiol] 2023 May 20; Vol. 2023, pp. 1147352. Date of Electronic Publication: 2023 May 20 (Print Publication: 2023).
Typ publikacji:: Journal Article
MeSH Terms:: Acute Coronary Syndrome*/drug therapy
Percutaneous Coronary Intervention*/methods
Humans ; Clopidogrel/therapeutic use ; Ticagrelor/therapeutic use ; Prasugrel Hydrochloride/adverse effects ; Purinergic P2Y Receptor Antagonists/adverse effects ; Retrospective Studies ; Hemorrhage/chemically induced ; Hemorrhage/epidemiology ; Ischemia ; Platelet Aggregation Inhibitors/adverse effects ; Treatment Outcome

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 9.

Tytuł:: Long-term use of clopidogrel versus ticagrelor or prasugrel in patients with acute myocardial infarction after percutaneous coronary intervention.
Autorzy:: Kim Y; College of Nursing, Chonnam National University, Gwangju, Korea.
Jeong MH; Department of Cardiology, Chonnam National University Hospital and Medical School, Gwangju, Korea.
An M; College of Nursing, Chonnam National University, Gwangju, Korea.
Cho K; Department of Cardiology, Chonnam National University Hospital and Medical School, Gwangju, Korea.
Hong Y; Department of Cardiology, Chonnam National University Hospital and Medical School, Gwangju, Korea.
Kim J; Department of Cardiology, Chonnam National University Hospital and Medical School, Gwangju, Korea.
Ahn Y; Department of Cardiology, Chonnam National University Hospital and Medical School, Gwangju, Korea.; Pokaż więcej
Źródło:: PloS one [PLoS One] 2023 Feb 23; Vol. 18 (2), pp. e0278993. Date of Electronic Publication: 2023 Feb 23 (Print Publication: 2023).
Typ publikacji:: Journal Article
MeSH Terms:: Acute Coronary Syndrome*/drug therapy
Myocardial Infarction*/drug therapy
Myocardial Infarction*/surgery
Percutaneous Coronary Intervention*/adverse effects
Humans ; Clopidogrel/therapeutic use ; Platelet Aggregation Inhibitors/adverse effects ; Prasugrel Hydrochloride/therapeutic use ; Purinergic P2Y Receptor Antagonists/therapeutic use ; Ticagrelor/therapeutic use ; Treatment Outcome

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 10.

Tytuł:: Clopidogrel versus ticagrelor in East Asian patients aged 75 years or older with acute coronary syndrome: observations from the GF-APT registry.
Autorzy:: Xi Z; Department of Cardiology, Coronary Artery Disease Center, State Key Laboratory of Cardiovascular Disease, Fuwai Hospital, National Center for Cardiovascular Diseases, Peking Union Medical College, Chinese Academy of Medical Sciences, Beijing, HE, China.
Qiu Z; Peking University Health Science Center, Beijing, HE, China.
Li J; Department of Cardiology and Macrovascular Disease, Beijing Tiantan Hospital, Capital Medical University, Beijing, HE, China.
Qiu H; Department of Cardiology, Coronary Artery Disease Center, State Key Laboratory of Cardiovascular Disease, Fuwai Hospital, National Center for Cardiovascular Diseases, Peking Union Medical College, Chinese Academy of Medical Sciences, Beijing, HE, China.
Guo T; Thrombosis Center, State Key Laboratory of Cardiovascular Disease, Fuwai Hospital, National Center for Cardiovascular Diseases, Peking Union Medical College, Chinese Academy of Medical Sciences, Beijing, HE, China.
Wang Y; Department of Cardiology, Coronary Artery Disease Center, State Key Laboratory of Cardiovascular Disease, Fuwai Hospital, National Center for Cardiovascular Diseases, Peking Union Medical College, Chinese Academy of Medical Sciences, Beijing, HE, China.
Zheng J; Department of Cardiology, Coronary Artery Disease Center, State Key Laboratory of Cardiovascular Disease, Fuwai Hospital, National Center for Cardiovascular Diseases, Peking Union Medical College, Chinese Academy of Medical Sciences, Beijing, HE, China.
Gao Y; Department of Cardiology, Coronary Artery Disease Center, State Key Laboratory of Cardiovascular Disease, Fuwai Hospital, National Center for Cardiovascular Diseases, Peking Union Medical College, Chinese Academy of Medical Sciences, Beijing, HE, China.
Gao R; Department of Cardiology, Coronary Artery Disease Center, State Key Laboratory of Cardiovascular Disease, Fuwai Hospital, National Center for Cardiovascular Diseases, Peking Union Medical College, Chinese Academy of Medical Sciences, Beijing, HE, China.; Pokaż więcej
Źródło:: Platelets [Platelets] 2022 Nov 17; Vol. 33 (8), pp. 1270-1278. Date of Electronic Publication: 2022 Sep 01.
Typ publikacji:: Journal Article
MeSH Terms:: Acute Coronary Syndrome*/therapy
Percutaneous Coronary Intervention*
Aged ; Clopidogrel/therapeutic use ; Dimaprit/analogs & derivatives ; Fibrinolytic Agents/therapeutic use ; Hemorrhage/epidemiology ; Hemorrhage/etiology ; Humans ; Platelet Aggregation Inhibitors/adverse effects ; Registries ; Ticagrelor/therapeutic use ; Treatment Outcome

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 11.

Tytuł:: High-Dose Clopidogrel versus Ticagrelor in CYP2C19 intermediate or poor metabolizers after percutaneous coronary intervention: A Meta-Analysis of Randomized Trials.
Autorzy:: Sheng XY; Integrated Hospital of Traditional Chinese Medicine, Southern Medical University, Guangzhou, China.
An HJ; General Hospital of Southern Theatre Command, PLA, Guangzhou, China.
He YY; Shenzhen Children's Hospital, Shenzhen, China.
Ye YF; The Fifth Affiliated Hospital, Sun Yat-Sen University, Zhuhai, China.
Zhao JL; Integrated Hospital of Traditional Chinese Medicine, Southern Medical University, Guangzhou, China.
Li S; Integrated Hospital of Traditional Chinese Medicine, Southern Medical University, Guangzhou, China.; Pokaż więcej
Źródło:: Journal of clinical pharmacy and therapeutics [J Clin Pharm Ther] 2022 Aug; Vol. 47 (8), pp. 1112-1121. Date of Electronic Publication: 2022 Apr 09.
Typ publikacji:: Journal Article; Meta-Analysis; Review
MeSH Terms:: Acute Coronary Syndrome*/drug therapy
Percutaneous Coronary Intervention*
Aspirin ; Clopidogrel ; Cytochrome P-450 CYP2C19/genetics ; Dyspnea/chemically induced ; Dyspnea/drug therapy ; Hemorrhage/chemically induced ; Hemorrhage/drug therapy ; Humans ; Platelet Aggregation Inhibitors ; Randomized Controlled Trials as Topic ; Ticagrelor ; Treatment Outcome

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 12.

Tytuł:: Dual Antiplatelet Therapy in Patients Aged 75 Years and Older with Coronary Artery Disease: A Meta-Analysis and Systematic Review.
Autorzy:: Saint Croix G; Columbia University Division of Cardiology at Mount Sinai Medical Center, Miami Beach, Florida, USA.
Lacy SC; Loyola University Medical Center, Maywood, Illinois, USA.
Gazzhal A; Columbia University Division of Cardiology at Mount Sinai Medical Center, Miami Beach, Florida, USA.
Ibrahim M; Temple University Medical Center, Philadelphia, Pennsylvania, USA.
Gjergjindreaj M; Columbia University Division of Cardiology at Mount Sinai Medical Center, Miami Beach, Florida, USA.
Perez J; Columbia University Division of Cardiology at Mount Sinai Medical Center, Miami Beach, Florida, USA.
Shehadeh M; Columbia University Division of Cardiology at Mount Sinai Medical Center, Miami Beach, Florida, USA.
Vedantam K; Columbia University Division of Cardiology at Mount Sinai Medical Center, Miami Beach, Florida, USA.
Torres C; Columbia University Division of Cardiology at Mount Sinai Medical Center, Miami Beach, Florida, USA.
Beohar N; Columbia University Division of Cardiology at Mount Sinai Medical Center, Miami Beach, Florida, USA.
Escolar E; Columbia University Division of Cardiology at Mount Sinai Medical Center, Miami Beach, Florida, USA.; Pokaż więcej
Źródło:: Journal of interventional cardiology [J Interv Cardiol] 2022 Sep 15; Vol. 2022, pp. 3111840. Date of Electronic Publication: 2022 Sep 15 (Print Publication: 2022).
Typ publikacji:: Journal Article; Meta-Analysis; Systematic Review
MeSH Terms:: Acute Coronary Syndrome*/drug therapy
Dual Anti-Platelet Therapy*/adverse effects
Platelet Aggregation Inhibitors*/adverse effects
Aged ; Clopidogrel/adverse effects ; Hemorrhage/chemically induced ; Humans ; Prasugrel Hydrochloride/adverse effects ; Risk Assessment ; Ticagrelor/adverse effects ; Treatment Outcome

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 13.

Tytuł:: Risk of major adverse cardiovascular events of CYP2C19 loss-of-function genotype guided prasugrel/ticagrelor vs clopidogrel therapy for acute coronary syndrome patients undergoing percutaneous coronary intervention: a meta-analysis.
Autorzy:: Biswas M; Department of Pharmacy, University of Rajshahi, Rajshahi, Bangladesh.
Kali MSK; Department of Pharmacy, University of Rajshahi, Rajshahi, Bangladesh.
Biswas TK; Department of Medicine, Faridpur Medical College Hospital, Faridpur, Bangladesh.
Ibrahim B; School of Pharmaceutical Sciences, Universiti Sains Malaysia, Penang, Malaysia.; Pokaż więcej
Źródło:: Platelets [Platelets] 2021 Jul 04; Vol. 32 (5), pp. 591-600. Date of Electronic Publication: 2020 Jul 14.
Typ publikacji:: Journal Article; Meta-Analysis
MeSH Terms:: Acute Coronary Syndrome/*drug therapy
Clopidogrel/*therapeutic use
Cytochrome P-450 CYP2C19/*metabolism
Platelet Aggregation Inhibitors/*therapeutic use
Prasugrel Hydrochloride/*therapeutic use
Ticagrelor/*therapeutic use
Acute Coronary Syndrome/pathology ; Clopidogrel/pharmacology ; Female ; Genotype ; Humans ; Male ; Platelet Aggregation Inhibitors/pharmacology ; Prasugrel Hydrochloride/pharmacology ; Risk Factors ; Ticagrelor/pharmacology ; Treatment Outcome

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 14.

Tytuł:: Ticagrelor versus Clopidogrel in Patients with Severe Renal Insufficiency Undergoing PCI for Acute Coronary Syndrome.
Autorzy:: Chen Y; Department of Cardiology, Yue Bei People's Hospital, Shantou University Medical College, Shaoguan, China.
Tu S; Department of Cardiology, Yue Bei People's Hospital, Shantou University Medical College, Shaoguan, China.
Chen Z; Department of Cardiology, Yue Bei People's Hospital, Shantou University Medical College, Shaoguan, China.
Xia J; Department of Cardiology, Yue Bei People's Hospital, Shantou University Medical College, Shaoguan, China.
Chen B; Department of Cardiology, Yue Bei People's Hospital, Shantou University Medical College, Shaoguan, China.
Chen J; Department of Cardiology, Yue Bei People's Hospital, Shantou University Medical College, Shaoguan, China.
Liang J; Department of Cardiology, Yue Bei People's Hospital, Shantou University Medical College, Shaoguan, China.
Liu X; Department of Cardiology, Yue Bei People's Hospital, Shantou University Medical College, Shaoguan, China.
Tang L; Department of Cardiology, Yue Bei People's Hospital, Shantou University Medical College, Shaoguan, China.; Pokaż więcej
Źródło:: Journal of interventional cardiology [J Interv Cardiol] 2022 Jul 31; Vol. 2022, pp. 6476777. Date of Electronic Publication: 2022 Jul 31 (Print Publication: 2022).
Typ publikacji:: Journal Article
MeSH Terms:: Acute Coronary Syndrome*/drug therapy
Acute Coronary Syndrome*/surgery
Percutaneous Coronary Intervention*/adverse effects
Renal Insufficiency*/complications
Clopidogrel/therapeutic use ; Hemorrhage/chemically induced ; Humans ; Retrospective Studies ; Ticagrelor/therapeutic use ; Treatment Outcome

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 15.

Tytuł:: Efficacy and Safety of Ticagrelor in East Asian Patients with Acute Coronary Syndrome: A Meta-Analysis of Randomized Controlled Trials.
Autorzy:: Xie C; Department of Pharmacy, The First Affiliated Hospital of Soochow University, Suzhou, China.
Lin J; Department of Cardiology, The First Affiliated Hospital of Soochow University, Suzhou, China.
Qin Q; Department of Pharmacy, The First Affiliated Hospital of Soochow University, Suzhou, China.
Zhu J; Department of Pharmacy, The First Affiliated Hospital of Soochow University, Suzhou, China.; Pokaż więcej
Źródło:: Anatolian journal of cardiology [Anatol J Cardiol] 2022 Jun; Vol. 26 (6), pp. 434-441.
Typ publikacji:: Journal Article; Meta-Analysis
MeSH Terms:: Acute Coronary Syndrome*/drug therapy
Percutaneous Coronary Intervention*
Asian People ; Clopidogrel/adverse effects ; Hemorrhage/chemically induced ; Hemorrhage/epidemiology ; Humans ; Platelet Aggregation Inhibitors/adverse effects ; Randomized Controlled Trials as Topic ; Ticagrelor/therapeutic use ; Treatment Outcome

Czasopismo naukowe

na półce

Pełny tekst Szczegóły

Skocz do pozycji: 16.

Tytuł:: microRNA-605 rs2043556 polymorphisms affect clopidogrel therapy through modulation of CYP2B6 and P2RY12 in acute coronary syndrome patients.
Autorzy:: Zhou WL; Department of Geriatrics, National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University , Changsha, China.
Mo ZZ; Department of Geriatrics, National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University , Changsha, China.
Xiao FY; Department of Clinical Pharmacology, Xiangya Hospital, Central South University , Changsha, China.
Dai W; Department of Geriatrics, National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University , Changsha, China.
Wang G; Department of Clinical Pharmacology, Xiangya Hospital, Central South University , Changsha, China.
Zhou G; Department of Clinical Pharmacology, Xiangya Hospital, Central South University , Changsha, China.
Zhang W; Department of Clinical Pharmacology, Xiangya Hospital, Central South University , Changsha, China.
Chen BL; Department of Geriatrics, National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University , Changsha, China.; Pokaż więcej
Źródło:: Platelets [Platelets] 2020 Oct 02; Vol. 31 (7), pp. 897-905. Date of Electronic Publication: 2019 Nov 26.
Typ publikacji:: Journal Article
MeSH Terms:: Acute Coronary Syndrome/*drug therapy
Acute Coronary Syndrome/*genetics
Clopidogrel/*therapeutic use
Cytochrome P-450 CYP2B6/*metabolism
MicroRNAs/*metabolism
Purinergic P2Y Receptor Antagonists/*therapeutic use
Receptors, Purinergic P2Y12/*metabolism
Acute Coronary Syndrome/metabolism ; Adult ; Aged ; Aged, 80 and over ; Clopidogrel/pharmacology ; Cytochrome P-450 CYP2B6/genetics ; Female ; Genotype ; Humans ; Male ; MicroRNAs/genetics ; Middle Aged ; Polymorphism, Single Nucleotide ; Receptors, Purinergic P2Y12/genetics

Czasopismo naukowe

na półce

Pełny tekst Szczegóły

Skocz do pozycji: 17.

Tytuł:: Efficacy assessment of ticagrelor versus clopidogrel in Chinese patients with acute coronary syndrome undergoing percutaneous coronary intervention by data mining and machine-learning decision tree approaches.
Autorzy:: Xue Y; Department of Pharmacy and Therapeutics, School of Pharmacy, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.; Department of Clinical Pharmacy, Zhongshan Hospital, Fudan University, Shanghai, China.; Department of Pharmaceutical Sciences and Computational Chemical Genomics Screening Center, School of Pharmacy, NIH National Center of Excellence for Computational Drug Abuse Research, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.
Hu Z; Department of Pharmaceutical Sciences and Computational Chemical Genomics Screening Center, School of Pharmacy, NIH National Center of Excellence for Computational Drug Abuse Research, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.
Jing Y; Department of Pharmaceutical Sciences and Computational Chemical Genomics Screening Center, School of Pharmacy, NIH National Center of Excellence for Computational Drug Abuse Research, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.
Wu H; Department of Cardiology, Zhongshan Hospital, Fudan University, Shanghai, China.
Li X; Department of Clinical Pharmacy, Zhongshan Hospital, Fudan University, Shanghai, China.
Wang J; Department of Pharmaceutical Sciences and Computational Chemical Genomics Screening Center, School of Pharmacy, NIH National Center of Excellence for Computational Drug Abuse Research, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.
Seybert A; Department of Pharmacy and Therapeutics, School of Pharmacy, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.
Xie X; Department of Pharmaceutical Sciences and Computational Chemical Genomics Screening Center, School of Pharmacy, NIH National Center of Excellence for Computational Drug Abuse Research, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.
Lv Q; Department of Clinical Pharmacy, Zhongshan Hospital, Fudan University, Shanghai, China.; Pokaż więcej
Źródło:: Journal of clinical pharmacy and therapeutics [J Clin Pharm Ther] 2020 Oct; Vol. 45 (5), pp. 1076-1086. Date of Electronic Publication: 2020 Jul 06.
Typ publikacji:: Comparative Study; Journal Article
MeSH Terms:: Acute Coronary Syndrome/*drug therapy
Clopidogrel/*administration & dosage
Percutaneous Coronary Intervention/*methods
Ticagrelor/*administration & dosage
Aged ; Algorithms ; Asian People ; Clopidogrel/adverse effects ; Data Mining ; Decision Trees ; Female ; Hemorrhage/chemically induced ; Hospitalization ; Humans ; Machine Learning ; Male ; Middle Aged ; Pilot Projects ; Platelet Aggregation Inhibitors/administration & dosage ; Platelet Aggregation Inhibitors/adverse effects ; Retrospective Studies ; Ticagrelor/adverse effects

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 18.

Tytuł:: Fewer gastrointestinal bleeds with ticagrelor and prasugrel compared with clopidogrel in patients with acute coronary syndrome following percutaneous coronary intervention.
Autorzy:: Abraham NS; Division of Gastroenterology and Hepatology, Department of Medicine, Mayo Clinic, Scottsdale, AZ, USA.; Mayo Clinic Robert D. and Patricia E. Kern Center for the Science of Health Care Delivery, Rochester, MN, USA.; Division of Health Care Policy and Research, Mayo Clinic, Rochester, MN, USA.
Yang EH; Cardiovascular Diseases, Mayo Clinic, Phoenix, AZ, USA.
Noseworthy PA; Mayo Clinic Robert D. and Patricia E. Kern Center for the Science of Health Care Delivery, Rochester, MN, USA.; Cardiovascular Diseases, Mayo Clinic, Rochester, MN, USA.
Inselman J; Mayo Clinic Robert D. and Patricia E. Kern Center for the Science of Health Care Delivery, Rochester, MN, USA.
Yao X; Mayo Clinic Robert D. and Patricia E. Kern Center for the Science of Health Care Delivery, Rochester, MN, USA.; Division of Health Care Policy and Research, Mayo Clinic, Rochester, MN, USA.
Herrin J; Division of Cardiology, Yale School of Medicine, New Haven, CT, USA.
Sangaralingham LR; Mayo Clinic Robert D. and Patricia E. Kern Center for the Science of Health Care Delivery, Rochester, MN, USA.
Ngufor C; Mayo Clinic Robert D. and Patricia E. Kern Center for the Science of Health Care Delivery, Rochester, MN, USA.; Division of Health Care Policy and Research, Mayo Clinic, Rochester, MN, USA.
Shah ND; Mayo Clinic Robert D. and Patricia E. Kern Center for the Science of Health Care Delivery, Rochester, MN, USA.; Division of Health Care Policy and Research, Mayo Clinic, Rochester, MN, USA.; OptumLabs, Cambridge, MA, USA.; Pokaż więcej
Źródło:: Alimentary pharmacology & therapeutics [Aliment Pharmacol Ther] 2020 Aug; Vol. 52 (4), pp. 646-654. Date of Electronic Publication: 2020 Jul 13.
Typ publikacji:: Journal Article; Research Support, U.S. Gov't, P.H.S.
MeSH Terms:: Percutaneous Coronary Intervention*/adverse effects
Percutaneous Coronary Intervention*/methods
Acute Coronary Syndrome/*drug therapy
Acute Coronary Syndrome/*surgery
Clopidogrel/*adverse effects
Gastrointestinal Hemorrhage/*chemically induced
Prasugrel Hydrochloride/*adverse effects
Ticagrelor/*adverse effects
Acute Coronary Syndrome/epidemiology ; Aged ; Clopidogrel/therapeutic use ; Cohort Studies ; Female ; Gastrointestinal Hemorrhage/epidemiology ; Humans ; Male ; Middle Aged ; Platelet Aggregation Inhibitors/adverse effects ; Postoperative Complications/chemically induced ; Postoperative Complications/epidemiology ; Postoperative Complications/prevention & control ; Prasugrel Hydrochloride/therapeutic use ; Retrospective Studies ; Thromboembolism/epidemiology ; Thromboembolism/prevention & control ; Ticagrelor/therapeutic use ; Treatment Outcome ; United States/epidemiology

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 19.

Tytuł:: Efficacy and safety of switching from ticagrelor to clopidogrel during the early and late phase in acute coronary syndrome patients after percutaneous coronary intervention.
Autorzy:: Wang C; Emergency and Critical Care Center, Beijing Anzhen Hospital, Capital Medical University, Beijing Institute of Heart Lung and Blood Vessel Disease, Beijing, China.
Zheng W; Emergency and Critical Care Center, Beijing Anzhen Hospital, Capital Medical University, Beijing Institute of Heart Lung and Blood Vessel Disease, Beijing, China.
Shaqdan A; Division of Cardiology, Massachusetts General Hospital, Boston, Massachusetts, United States.
Wang C; Emergency and Critical Care Center, Beijing Anzhen Hospital, Capital Medical University, Beijing Institute of Heart Lung and Blood Vessel Disease, Beijing, China.
Qin X; Emergency and Critical Care Center, Beijing Anzhen Hospital, Capital Medical University, Beijing Institute of Heart Lung and Blood Vessel Disease, Beijing, China.
Zhao X; Emergency and Critical Care Center, Beijing Anzhen Hospital, Capital Medical University, Beijing Institute of Heart Lung and Blood Vessel Disease, Beijing, China.
Wang X; Emergency and Critical Care Center, Beijing Anzhen Hospital, Capital Medical University, Beijing Institute of Heart Lung and Blood Vessel Disease, Beijing, China.
Yuan L; Emergency and Critical Care Center, Beijing Anzhen Hospital, Capital Medical University, Beijing Institute of Heart Lung and Blood Vessel Disease, Beijing, China.
Nie S; Emergency and Critical Care Center, Beijing Anzhen Hospital, Capital Medical University, Beijing Institute of Heart Lung and Blood Vessel Disease, Beijing, China.
Liu R; Emergency and Critical Care Center, Beijing Anzhen Hospital, Capital Medical University, Beijing Institute of Heart Lung and Blood Vessel Disease, Beijing, China.; Pokaż więcej
Źródło:: Platelets [Platelets] 2020; Vol. 31 (3), pp. 337-343. Date of Electronic Publication: 2019 May 01.
Typ publikacji:: Journal Article
MeSH Terms:: Drug Substitution*
Acute Coronary Syndrome/*blood
Acute Coronary Syndrome/*drug therapy
Clopidogrel/*therapeutic use
Percutaneous Coronary Intervention/*adverse effects
Platelet Aggregation Inhibitors/*therapeutic use
Acute Coronary Syndrome/diagnosis ; Acute Coronary Syndrome/surgery ; China ; Clopidogrel/administration & dosage ; Clopidogrel/adverse effects ; Electrocardiography ; Follow-Up Studies ; Hemorrhage/etiology ; Hemorrhage/prevention & control ; Humans ; Kaplan-Meier Estimate ; Magnetic Resonance Angiography ; Percutaneous Coronary Intervention/methods ; Platelet Aggregation Inhibitors/administration & dosage ; Platelet Aggregation Inhibitors/adverse effects ; Retrospective Studies ; Ticagrelor/administration & dosage ; Ticagrelor/adverse effects ; Ticagrelor/therapeutic use ; Tomography, X-Ray Computed ; Treatment Outcome